Vitae/Boehringer's diabetes drug fails in metformin arm of Phase II trial

30 June 2015

Clinical-stage biotech company Vitae Pharmaceuticals (Nasdaq: VTAE) has announced that its drug BI187004/VTP-34072 failed in the metformin arm of an ongoing Phase II trial in overweight type 2 diabetes.

BI187004/VTP-34072 is a potential first-in-class 11β-hydroxysteroid dehydrogenase type 1, discovered by Vitae and under development by German family-owned drug major Boehringer Ingelheim, under a deal that generated an upfront payment of $36.5 million for Vitae (The Pharma Letter October 22, 2007).

The safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of the drug as a monotherapy or as an add-on to metformin are being investigated over 28 days as part of a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK